Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Routine surveillance of kidney allograft rejection using a fully automated urinary CXCL9 and CXCL10 immunoassay

Claire Tinel, Virginia Sauvaget, Laïla Aouni, View ORCID ProfileBaptiste Lamarthée, Charlotte Leclaire, Christophe Legendre, Pierre Marquet, Corinne Normand, Marion Rabant, Fabiola Terzi, Dany Anglicheau
doi: https://doi.org/10.1101/2023.07.26.23293106
Claire Tinel
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
2Department of Nephrology and Kidney Transplantation, Dijon University Hospital, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia Sauvaget
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laïla Aouni
3Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baptiste Lamarthée
4Université de Franche-Comté, UBFC, EFS, Inserm RIGHT, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Baptiste Lamarthée
Charlotte Leclaire
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Legendre
3Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Marquet
5Limoges University Hospital, University of Limoges, Inserm, Department of Nephrology, Dialysis and Transplantation, Limoges, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corinne Normand
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Rabant
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
6Pathology Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiola Terzi
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dany Anglicheau
1Necker-Enfants Malades Institute, Inserm U1151, Université de Paris Cité, Paris, France
3Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dany.anglicheau{at}aphp.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background For kidney transplant recipients, assessing non-invasively the individualized risk of acute rejection is one of the most unmet need. Urinary chemokines are one of the short-term most promising biomarkers, because of their simple and low-cost analytical method in easily accessible samples, and their high diagnostic performance consistently assessed over the last decade. In this study, we aimed at confronting all practical issues of routine implementation of kidney allograft rejection monitoring using urine CXCL9 and CXCL10.

Methods The next-generation immunoassay Ella® was investigated as feasible quantification platform, from sample collection to render of the results. Urine CXCL9/10 levels were measured using Ella® microfluidic cartridges, across preanalytical (sample preparation, storage conditions, freeze-thaw cycles) and analytical (linearity, ranges, intra/inter-assay variability) performances studies, and diagnostic accuracy was assessed in comparison to the ELISA reference method, in urine samples from previously published cohorts.

Results Upon assay preparation, Ella® appeared very efficient with a minimal workflow (urine sample thaw> centrifugation>1:2 dilution>loading) and a time to result of 90 minutes. Preanalytical studies showed high stability of urine CXCL9/10 levels across various temperatures (4° vs 25°C) and time (24/48/72H) before storage and over 5 freeze-thaw cycles. How complex urine matrix, analytical studies confirmed excellent linearity of dosage, as well as intra-assay (≤5%) and inter-assay precision. Across 1024 samples, Ella® results were highly correlated to those quantified by ELISA (P<0.0001), and further entered into our previously validated urine chemokine model. 268 out of the 1024 samples were collected at time of acute rejection (26.2%). In this cohort, accuracy was 0.85 for acute rejection diagnosis.

Conclusion Ella® fulfils all prerequisites for clinical implementation of urinary chemokines monitoring. It has proven a robust, easy-to-use platform with unprecedented validation to quantify urine chemokines.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The Emmanuel Boussard Foundation supported DA, LA, CT and VS, and DA received funds from the Day Solvay Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics Committee of Ile-de-France XI (#13016)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Disclosure: The authors of this manuscript declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. CT and DA are inventors of the model and OptimCare holds patents for the use of the model.

  • Funding: CT is supported by the Société Francophone de Transplantation. The Emmanuel Boussard Foundation supported DA, LA, LM, CT and VS, and DA received funds from the Day Solvay Foundation.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 28, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Routine surveillance of kidney allograft rejection using a fully automated urinary CXCL9 and CXCL10 immunoassay
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Routine surveillance of kidney allograft rejection using a fully automated urinary CXCL9 and CXCL10 immunoassay
Claire Tinel, Virginia Sauvaget, Laïla Aouni, Baptiste Lamarthée, Charlotte Leclaire, Christophe Legendre, Pierre Marquet, Corinne Normand, Marion Rabant, Fabiola Terzi, Dany Anglicheau
medRxiv 2023.07.26.23293106; doi: https://doi.org/10.1101/2023.07.26.23293106
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Routine surveillance of kidney allograft rejection using a fully automated urinary CXCL9 and CXCL10 immunoassay
Claire Tinel, Virginia Sauvaget, Laïla Aouni, Baptiste Lamarthée, Charlotte Leclaire, Christophe Legendre, Pierre Marquet, Corinne Normand, Marion Rabant, Fabiola Terzi, Dany Anglicheau
medRxiv 2023.07.26.23293106; doi: https://doi.org/10.1101/2023.07.26.23293106

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Transplantation
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)